Long-term effects of treatment of central precocious puberty with gonadotropin-releasing hormone analogs every three months.
Title | Long-term effects of treatment of central precocious puberty with gonadotropin-releasing hormone analogs every three months. |
Publication Type | Journal Article |
Year of Publication | 2020 |
Authors | Vatopoulou, A., Roos E., Daniilidis A., & Dinas K. |
Journal | Gynecol Endocrinol |
Volume | 36 |
Issue | 12 |
Pagination | 1124-1126 |
Date Published | 2020 Dec |
ISSN | 1473-0766 |
Abstract | BACKGROUND: Gonadotropin-releasing hormone (GnRH) analogs represent the treatment of choice in patients with central precocious puberty (CPP). Recently, GnRH analogs that can be administered every 3 months have been developed and appear to be as safe and effective as one-monthly formulations. However, there are limited data regarding its long term safety and efficacy profile. We aimed to evaluate the long-term safety and efficacy treatment of CPP with GnRH analogs every 3 months.METHODS: We prospectively studied all patients who were diagnosed with CPP in our center between January 2015 and December 2019. All patients were treated with intramuscular leuprolide acetate 11.25 mg every 3 months.RESULTS: Twenty-four patients with CPP were included in the study. Mean follow-up was 3.1 years. Height gain ranged between 4 and 6 cm. Bone mineral density (BMD) was not affected. Body mass index (BMI) increased in all subjects but none was obese at the end of follow-up.CONCLUSIONS: Treatment of patients with CPP with GnRH analogs every 3 months induces substantial increases in height and does not affect BMI or BMD. Therefore, it represents an attractive option for these young patients. |
DOI | 10.1080/09513590.2020.1770723 |
Alternate Journal | Gynecol Endocrinol |
PubMed ID | 32484003 |